SLC6A3 and Parkinson disease: To examine the method’s reproducibility, Russo et al. performed α-syn SAA in three different laboratories, utilizing the CSF of patients with either early or de novo PD (contrarily to Orrù et al.), healthy controls, and patients with parkinsonism but no evidence of dopaminergic deficits in DAT-SPECT [39,40].